Topical formulations let you target the scalp directly while limiting systemic exposure. The active ingredients — minoxidil for follicular blood flow, finasteride and dutasteride for DHT blockade, plus supporting actives like spironolactone (androgen-receptor blockade), levocetirizine (PGD2 antagonism), latanoprost (prostaglandin F2α pathway), calcitriol (vitamin D pathway), ciclopirox (antifungal/anti-inflammatory), pramoxine (anti-itch), caffeine, melatonin, ketoconazole, and tretinoin — are absorbed at the application site and act on the same biology of androgenetic alopecia that oral medications do, with a different side-effect profile.
Obsidian Genetics offers four compounded topical formulations: a Foundation Formula (Finasteride 0.1% / Minoxidil 6%) — the classic 5αRI + vasodilator baseline, an Advanced Multi-Active (D2) — 11 actives layering dual DHT block, prostaglandin, and vitamin-D signaling, a Complete Formula (D6) — 13 actives (adds Tretinoin and Spironolactone for maximum mechanism coverage), and a Sensitive Scalp Formula (D8) — 11 actives (Spironolactone-based, no Ketoconazole or Tretinoin) for men whose scalps don't tolerate keto or retinoids. Your provider matches the formulation to your hair-loss pattern, prior response, and tolerance.
Both compounds are prepared by a licensed compounding pharmacy and prescribed by a licensed provider following clinical review. Applied once daily to the scalp.
Includes ongoing provider care & support
Compounded medication · Platform access
Topical minoxidil is FDA-approved. Topical finasteride is well-studied off-label. Each supporting active in our compounded solutions has its own peer-reviewed rationale.
Individual results vary. Topical formulations reduce systemic absorption substantially compared to oral, but absorption still occurs and contraindications still apply. These are compounded prescription products prepared by a licensed compounding pharmacy. The Foundation Formula, Advanced Multi-Active (D2), Complete Formula (D6), and Sensitive Scalp Formula (D8) blends are not FDA-approved as combined finished products; each is prescribed off-label by a licensed provider following clinical review.
Finasteride inhibits Type II 5-alpha reductase, the enzyme that converts testosterone to DHT. In androgenetic alopecia, DHT binds to receptors in genetically susceptible hair follicles, triggering miniaturization. Reducing scalp DHT by approximately 64% (Drake 1999) substantially blunts this hormonal driver of hair loss.
Minoxidil is a potassium channel opener that dilates blood vessels around hair follicles. It increases oxygen and nutrient delivery to the hair bulb, extending the anagen (active growth) phase of the hair cycle. Better blood flow means better fueling of the follicle.
Finasteride stops the hormonal damage; minoxidil simultaneously stimulates regrowth and prolongs the growth phase. Used together, they address both cause and consequence of androgenic alopecia far more effectively than either alone.
Topical formulations limit systemic exposure. Multi-active formulations layer mechanisms. Here's how the options compare.
| Comparison | Single Topical (Minoxidil 5%) | Oral (Finasteride / Min+Fin) | Topical Multi-Active (this product) |
|---|---|---|---|
| Delivery route | Topical to scalp | Systemic via GI | ✓ Topical to scalp |
| Systemic exposure | Low | Full systemic | Low |
| DHT blockade at scalp | None | Strong (oral 5α-reductase inhibition) | ✓ Strong (topical FIN/DUT) |
| Vasodilation / growth stimulation | Strong | Moderate (oral minoxidil) | ✓ Strong (minoxidil 5%) |
| Supporting actives | None | None | Caffeine, melatonin, ketoconazole, tretinoin, rosemary oil |
| Best patient profile | Those wanting topical-only with one active | Those okay with systemic dosing | Those wanting layered topical action with limited systemic exposure |
| Main limitation | Single-mechanism only | Systemic side-effect profile | ✓ Requires daily topical application |
Both mechanisms activate. DHT suppression begins immediately; minoxidil stimulation begins within days. Many patients experience temporary shedding in weeks 2-4; this is normal and reflects the transition of old hairs out of the cycle. Do not stop treatment during this phase.
Shedding phase resolves. Hair density stabilizes as new growth begins to mature. DHT suppression is now well-established (approximately 64% scalp DHT reduction, per Drake 1999). Circulation improvements are supporting new follicle activity. Subtle improvements may become noticeable by month 5-6.
Measurable improvement in hair count and density. New hairs are thicker and more pigmented. Hairline may appear fuller; crown density improving. Most patients report noticeable results by month 6-9 of consistent daily use. Improvements continue to compound through month 12.
Full response achieved. Continued daily use maintains results. Hair loss stops; density plateaus at maximum improvement. To maintain these gains, consistent use is required indefinitely. Missing doses or stopping treatment results in gradual loss of benefit.
Topical formulations limit systemic exposure substantially compared to oral, but absorption still occurs and contraindications still apply. Here is what to know.
Topical finasteride / dutasteride: Even applied topically, some systemic absorption occurs. Patients with a history of prostate cancer or significantly elevated PSA, and any patient who has previously experienced sexual side effects on oral 5α-reductase inhibitors, should disclose this during intake. Pregnancy / fetal exposure: Pregnant women must not handle these solutions; topical 5α-reductase inhibitors can cause feminization of male fetuses. Wash hands thoroughly after each application and avoid skin-to-skin scalp contact with anyone pregnant or trying to become pregnant. Topical minoxidil: Do not apply to broken or irritated skin. Avoid getting solution in eyes; rinse thoroughly if contact occurs. Patients with uncontrolled cardiovascular disease should discuss before use; while topical absorption is much lower than oral, it is not zero. Ketoconazole: Local irritation, dryness, or transient hair texture changes can occur. Tretinoin (D6 only): May cause mild scalp redness, dryness, or photosensitivity in early weeks; reduces with continued use. Spironolactone (D6 and D8 only): Rare topical absorption can affect potassium — routine monitoring is not required for topical dosing but disclose kidney disease or potassium-sparing medications during intake. Latanoprost (D2, D6, D8): Can darken skin pigmentation in application zone with prolonged use; avoid contact with eyes. Ciclopirox (D2, D6, D8): Generally well-tolerated; rare local irritation possible. Drug interactions: Disclose all medications during intake. For men only: These topical formulations are not recommended for women — finasteride/dutasteride exposure risk to potential pregnancies is the limiting factor.
All four are compounded prescription topicals applied once daily. They differ in number of actives, added anti-androgenic mechanisms (spironolactone, dutasteride), retinoid signaling (tretinoin), and antifungal/anti-inflammatory support (ketoconazole, ciclopirox). Your provider will confirm the right fit during intake.
Finasteride 0.1% / Minoxidil 6%
What it is: The classic two-active baseline — topical finasteride (5α-reductase inhibitor) paired with minoxidil (potassium channel opener / vasodilator) at 6% concentration. The same two mechanisms that make oral finasteride and topical minoxidil the FDA-standard for AGA, delivered together in one daily application.
Best for:
Why pick this: Topical finasteride reduces scalp DHT comparably to oral 1mg dosing while substantially lowering systemic exposure (Caserini 2014). Minoxidil 6% improves follicular blood flow and prolongs anagen. Two mechanisms, minimal added actives, lowest cost.
Min 6% / Ketoconazole 1.7% / Levocetirizine 1% / Dutasteride 0.25% / Finasteride 0.25% / Melatonin 0.1% / Caffeine 0.2% / Calcitriol 0.004% / Latanoprost 0.005% / Ciclopirox 1% / Pramoxine 1%
What it is: Dual 5α-reductase blockade (finasteride + dutasteride at reduced concentrations) plus five additional mechanistic pathways: PGD2 antagonism (levocetirizine), prostaglandin F2α (latanoprost), vitamin-D receptor signaling (calcitriol), antifungal/anti-inflammatory (ketoconazole + ciclopirox), and follicular stimulation (caffeine + melatonin). Pramoxine reduces scalp itch from the higher active load.
Best for:
Why pick this: Dual 5αRI at low doses spreads DHT suppression across two enzymes at reduced individual exposure. Latanoprost and calcitriol target pathways no monotherapy addresses. Levocetirizine may modulate the PGD2-AGA pathway (Garza 2012). Ciclopirox handles fungal/inflammatory contributors that ketoconazole alone can miss.
Min 6% / Ketoconazole 1.7% / Tretinoin 0.01% / Levocetirizine 1% / Dutasteride 0.25% / Finasteride 0.25% / Spironolactone 0.5% / Melatonin 0.1% / Caffeine 0.2% / Calcitriol 0.004% / Latanoprost 0.005% / Ciclopirox 1% / Pramoxine 1%
What it is: Our maximum-coverage formulation — everything in D2 plus two additional mechanisms: tretinoin (retinoid signaling + enhanced minoxidil penetration) and spironolactone (topical androgen-receptor blockade). Thirteen actives covering DHT enzymes, androgen receptor, prostaglandin F2α, PGD2, vitamin-D pathway, retinoid signaling, antifungal/anti-inflammatory, follicular stimulation, and anti-itch support.
Best for:
Why pick this: Adds two orthogonal mechanisms on top of D2. Spironolactone blocks DHT at the androgen receptor itself — a third anti-androgenic layer on top of dual 5αRI. Tretinoin enhances minoxidil penetration and has independent hair-growth signaling effects (Bazzano 1986 — 66% terminal regrowth with tretinoin + minoxidil). The most comprehensive formulation in the catalog.
Min 6% / Levocetirizine 1% / Dutasteride 0.25% / Finasteride 0.25% / Spironolactone 0.5% / Melatonin 0.1% / Caffeine 0.2% / Calcitriol 0.004% / Latanoprost 0.005% / Ciclopirox 1% / Pramoxine 1%
What it is: D6-tier coverage minus ketoconazole and tretinoin — for men whose scalps are irritated by keto or retinoid actives. Retains dual 5αRI, spironolactone androgen-receptor blockade, prostaglandin pathway, vitamin-D signaling, ciclopirox (milder antifungal alternative to keto), and anti-itch support.
Best for:
Why pick this: Keeps the three anti-androgenic mechanisms (finasteride + dutasteride + spironolactone) plus the prostaglandin/vitamin-D pathways from D6, but drops the two most common irritant actives (ketoconazole 1.7% and tretinoin 0.01%). Ciclopirox 1% remains as a gentler antifungal option.
Minoxidil 6% — Potassium channel opener / vasodilator. Improves follicular blood flow and prolongs anagen. FDA-approved for AGA at 5%; 6% used in compounding for enhanced vasodilation. Present in all four formulations.
Finasteride 0.1–0.25% — Type II 5α-reductase inhibitor. Reduces scalp DHT comparably to oral 1mg with lower systemic absorption (Caserini 2014 / Hu 2022 Phase III RCT). Present in all four formulations.
Dutasteride 0.25% — Dual Type I & Type II 5α-reductase inhibitor. ~3× more potent DHT suppression than finasteride. Used at reduced dose alongside finasteride in D2, D6, and D8 for broader 5αRI coverage.
Spironolactone 0.5% — Topical androgen-receptor antagonist. Adds a third anti-androgenic layer by blocking DHT at the receptor itself (alongside dual 5αRI). Used in D6 and D8.
Tretinoin 0.01% — Retinoid that enhances minoxidil penetration and has independent hair-growth effects via follicular signaling. Bazzano 1986 showed 66% terminal regrowth with tretinoin + minoxidil combo. Used only in D6.
Ketoconazole 1.7% — Anti-inflammatory and antifungal with AGA evidence (Fields 2020 systematic review). Helps when scalp inflammation contributes to hair loss. Used in D2 and D6.
Levocetirizine 1% — H1 antihistamine. Emerging evidence that PGD2 (prostaglandin D2) accumulation contributes to AGA (Garza 2012); antihistamines may modulate this pathway. Used in D2, D6, D8.
Latanoprost 0.005% — Prostaglandin F2α analogue (same mechanism as the Latisse eyelash product). Small RCTs in scalp AGA suggest increased hair density. Note: Can darken skin pigmentation in application zone; avoid eye contact. Used in D2, D6, D8.
Calcitriol 0.004% — Active vitamin-D3 metabolite (1,25-dihydroxycholecalciferol). Vitamin-D receptor signaling regulates the hair follicle cycle; calcitriol supports anagen induction. Used in D2, D6, D8.
Caffeine 0.2% — Penetration enhancer and follicular stimulant. Dhurat 2017 found topical caffeine 0.2% non-inferior to topical minoxidil 5% in male AGA. Used in D2, D6, D8.
Melatonin 0.1% — Antioxidant with scalp-specific melatonin receptors. Topical 0.1% melatonin RCT showed improvement in AGA (Fischer 2004). Used in D2, D6, D8.
Ciclopirox 1% — Broad-spectrum antifungal with anti-inflammatory activity. Alternative or complement to ketoconazole; effective against Malassezia species implicated in scalp inflammation. Used in D2, D6, D8 (and remains in D8 when ketoconazole is dropped).
Pramoxine 1% — Topical anesthetic that reduces scalp itch and irritation from the higher active load in multi-active formulations. Non-steroidal. Used in D2, D6, D8.
All options include: physician consultation · compounded medication · ongoing provider support · free shipping. Not sure which is right? Your Obsidian Genetics provider will discuss your hair-loss pattern, prior treatment history, and tolerance during intake. For oral hair-loss options (Finasteride 1mg, Min+Fin combo tablet, Premium 5-Active capsule, Dutasteride mono capsule), see the Oral Hair Loss page. For women, see the Women's Hair Loss page.
Important: The Foundation Formula, Advanced Multi-Active (D2), Complete Formula (D6), and Sensitive Scalp Formula (D8) topical solutions described on this page are compounded preparations. Topical minoxidil 5% is FDA-approved for androgenetic alopecia; 6% used in these formulations is compounded off-label. The other actives (finasteride, dutasteride, spironolactone, tretinoin, ketoconazole, levocetirizine, latanoprost, calcitriol, ciclopirox, pramoxine, caffeine, melatonin) are FDA-approved, prescription, or generally recognized as safe for various indications, but the combined topical formulations are prepared by a licensed compounding pharmacy and are not FDA-approved as finished drug products. Compounded medications are prescribed off-label and their effectiveness has not been independently verified by the FDA. Pregnant women must not handle these products. For men only — topical 5α-reductase inhibitors carry fetal exposure risk. Cited research reflects published clinical studies of the individual actives or related compounded formulations. Prescription required. Individual results vary. All Obsidian Genetics prescriptions are issued following clinical review by a licensed provider. © 2024 Obsidian Genetics. All rights reserved.